Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
The Journal of Infectious Diseases|November 9, 2000
The GB virus C/hepatitis G virus replicates in hepatocytes without causing liver disease in healthy blood donorsR Halasz, M Sällberg, S Lundholm, et al.
Liver|August 1, 1994
Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment courseO Reichard, H Glaumann, G Norkrans, et al.
Journal of Hepatology|April 27, 2001
Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitisK A Fleming, K M Boberg, H Glaumann, et al.
Liver|April 1, 1987
Evaluation of an oral bile acid loading test for assessment of liver function in chronic hepatitis. A comparison with fasting serum bile acids and i.v. galactose elimination testU Foberg, C Broström, A Frydén, et al.
Clinical and Experimental Immunology|March 1, 1992
Lymphocyte subsets and beta 2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects of interferon-alpha treatmentR Wejstål, G Norkrans, O Weiland, et al.
Hepatology (Baltimore, Md.)|April 1, 1995
Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatmentO Reichard, H Glaumann, A Frydén, et al.
Journal of Viral Hepatitis|May 30, 2008
Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirinO Weiland, A Hollander, L Mattsson, et al.
Scandinavian Journal of Gastroenterology|February 15, 2002
Obstructive jaundice results in increased liver expression of uncoupling protein 2 and intact skeletal muscle glucose metabolism in the ratB Isaksson, C Rippe, R Simonoska, et al.
Blood|August 15, 1995
Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipientsP Ljungman, N Johansson, J Aschan, et al.
Gut|March 11, 2006
The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor alpha mediated liver diseaseL Frelin, E D Brenndörfer, G Ahlén, et al.
Pageof 12